Experts has a new look! Let us know what you think of the updates.

Provide feedback
Home
Scholarly Works
Estimating individual lifetime benefit and...
Conference

Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial

Authors

De Vries TI; Eikelboom JW; Bosch J; Westerink J; Dorresteijn JAN; Alings M; Dyal L; Berkowitz SD; Van der Graaf Y; Fox KAA

Volume

40

Pagination

pp. 1274-1274

Publisher

OXFORD UNIV PRESS

Publication Date

October 1, 2019

Name of conference

Congress of the European-Society-of-Cardiology (ESC) / World Congress of Cardiology

Conference place

Paris, FRANCE

Conference start date

August 31, 2019

Conference end date

September 4, 2019

Conference proceedings

EUROPEAN HEART JOURNAL

ISSN

0195-668X